Standpoint Research analyst Ronnie Moas says he's been presented with evidence by an analytics company that suggests OPKO Health may have been the subject of an illegal short selling attack. The analyst added that he gave the evidence to OPKO Health yesterday in a meeting with senior management. Moas thinks the stock could trade at $12-$16 by this time next year. OPKO may take legal action, announce a spin-off that "could crush the shorts," or just present good news from drug trials, Moas writes regarding the company's possible next steps. OPKO in early trading is down 7c to $6.10.